Question at position 62 SERMS have fewer side effects than using sex hormones to treat osteoporosis.TrueFalse单项选择题
A
True
B
False

Question

Question at position 62 SERMS have fewer side effects than using sex hormones to treat osteoporosis.TrueFalse

BlackTom AI · Accepted Answer

To begin, let's consider the statement in question about SERMs versus sex hormones for osteoporosis treatment.
Option 1: True. The claim is that SERMs have fewer side effects than using sex hormones to treat osteoporosis. In practice, SERMs such as raloxifene act as estrogen receptor modulators, providing estrogen-like effects on bone to help reduce fracture risk, while acting as antagonists in breast tissue and, in some cases, in the uterus. This receptor-selective action can lower the risk of certain estrogen-related adverse effects seen with systemic estrogen therapy, such as breast and endometrial stimulation. However, SERMs are not risk-free; they carry their own potential side effects, notably an increased risk of venous thromboembolism and occasionally hot flashes. Despite these caveats, the overall side effect profile of SERMs is often considered more favorable than that of systemic estrogen therapy for osteoporosis, which historically carries broader risks including thromboembolism, endometrial hyperplasia, and certain cancers depending on duration and context. Thus, the assertion that SERMs have fewer side effects than sex hormones is generally consistent with current pharmacologic reasoning, though clinicians still weigh individual patient risk factors.
Option 2: False. Saying that SERMs have more side effects than sex hormones would contradict the comparative risk considerations described above. While SERMs do have notable risks (e.g., DVT, hot flashes), systemic estrogen therapy for osteoporosis is associated with a distinct and sometimes higher array of risks such as thromboembolic events, endometrial changes, and potential cancers in exposed tissues. The blanket statement that SERMs have more side effects ignores these nuances and the mechanism by which SERMs limit estrogen activity in non-bone tissues. Therefore, labeling the claim as false would require disregarding established pharmacodynamic differences and individual patient risk profiles.
In summary, the comparison hinges on the tissue-selective actions of SERMs versus the broader estrogen effects of sex hormones, with SERMs typically presenting a more favorable side-effect profile in many patient scenarios, though not without notable risks that must be monitored.

Question at position 62 SERMS have fewer side effects than using sex hormones to treat osteoporosis.TrueFalse单项选择题

类似问题

Vitamin K may increase bone density in people with osteoporosis.

True or false: A patient with osteoporosis would be given calcitonin to help strengthen bones.

Which of the following statements concerning osteoporosis treatments is/are true? Select all that apply.

Is the following statement true or false? In the products of methylation-hydrolysis, every -OH group corresponds to the position of a glycosidic bond in the starting polysaccharide.

Which of the follwoing structures represents amylopectin?

Which of the following is true about an aldopentose?I. It is a monosaccharide.II. It contains a CHO groupIII. It is a disaccharide.IV. It is an oligosaccharide.

For stock A, we have 𝛽 𝑖 = 0.70. Suppose the expected market risk premium next year is 9% and the risk-free rate is 3%. What is the expected return of this stock based on the CAPM? (Please answer in % and round to 2 decimal places. If the answer is 8.057%, then in the box, write 8.06)

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单